Jun 04, 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept
Jun 03, 2020
Novavax Selects AGC Biologics to Manufacture Matrix-M(TM) Adjuvant for Novel COVID-19 Vaccine
Jun 03, 2020
Eleva's Drug Candidate to Be Examined for Use in COVID-19 Treatment
Jun 03, 2020
Global Bioanalytical Testing Services Market Outlook, 2020-2025 - Outbreak of COVID-19 Boosting Infectious Disease Applications
Jun 02, 2020
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference
Jun 02, 2020
World Markets for Interferons, 2030 (COVID-19 Adjusted) - Roche, Merck, BMS, Biogen, Bayer, Zydus Cadila, Novartis, Pfizer, Biosidus, and Nanogen are the Major Players
Jun 02, 2020
Catalent Appoints Charles Lickfold as Chief Information Officer
Jun 02, 2020
Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative Drugs
Jun 01, 2020
Aruvant Appoints Dr. Palaniappan as Chief Technology Officer
Jun 01, 2020
Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
Jun 01, 2020
AGC Biologics Acquires Commercial Facility, Expanding Global Service Offerings
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
May 31, 2020
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
May 28, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
May 28, 2020
Clinical Studies & Research Progressing for Finding Cure for Glioblastoma
May 27, 2020
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
May 27, 2020
RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic
May 26, 2020
The Subcutaneous Biologic Drugs and Affiliated Technologies Market is Estimated to be Worth Over USD 180 Billion by 2030, Claims Roots Analysis
May 21, 2020
Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)